SCHEMBL1490848

SCHEMBL1490848

CC(C)(C)N(CCCNc1c(N)cnc2ccccc12)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.45
RAD52 P43351 3/20 0.45
KMT2A Q03164 2/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
SLC2A1 P11166 1/20 0.45
APOBEC3A P31941 1/20 0.45
APOBEC3G Q9HC16 1/20 0.45
MEN1 O00255 1/20 0.43
PKM P14618 1/20 0.43
CACNA2D1 P54289 1/20 0.40
BCHE P06276 4/20 0.40
ACHE P22303 3/20 0.40
TOP2A P11388 2/20 0.40
KDM4E B2RXH2 1/20 0.39
MITF O75030 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
TTR P02766 1/20 0.39
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2505135 0.97 CACNA2D1 (0.45) POLBRAD52KMT2ARAB9ANPC1
SCHEMBL1490666 0.93 KMT2A (0.42) POLBRAD52KMT2ARAB9ANPC1
SCHEMBL7171113 0.88 KMT2A (0.40) POLBRAD52KMT2ARAB9ANPC1
SCHEMBL2891877 0.83 CHRM2 (0.51) POLBRAD52KMT2ARAB9ANPC1
SCHEMBL6105144 0.83 RXFP1 (0.35) RAB9ACACNA2D1BCHEACHEGAA
SCHEMBL1486511 0.81 NMT1 (0.44) ACHEKDM4EALDH1A1LMNA
SCHEMBL1486484 0.81 NMT1 (0.39) KMT2AMEN1ACHE
SCHEMBL2507712 0.81 CHRM2 (0.48) POLBRAD52KMT2ARAB9ANPC1
SCHEMBL2507709 0.81 CHRM2 (0.48) POLBRAD52KMT2ARAB9ANPC1
SCHEMBL1773910 0.80 CACNA2D1 (0.37) POLBKMT2ARAB9ANPC1SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598192-B2 Hydroxylamine substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-12-03 US disclosed
US-8436178-B2 Imidazoquinolines with immuno-modulating properties ASTRAZENECA AB (SE) 2013-05-07 US disclosed
US-7897767-B2 Oxime substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
US-20100280001-A1 IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280001-A1 IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES IFNG, FCGRT, IFNAR1 POLB 3901/4885RAD52 1464/4885KMT2A 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.